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Abstract
Chemotherapy is still the cornerstone for malaria control. Developing drugs against Plasmodium parasites and monitoring
their efficacy requires methods to accurately determine the parasite killing rate in response to treatment. Commonly used
techniques essentially measure metabolic activity as a proxy for parasite viability. However, these approaches are
susceptible to artefacts, as viability and metabolism are two parameters that are coupled during the parasite life cycle but
can be differentially affected in response to drug actions. Moreover, traditional techniques do not allow to measure the
speed-of-action of compounds on parasite viability, which is an essential efficacy determinant. We present here a
comprehensive methodology to measure in vitro the direct effect of antimalarial compounds over the parasite viability,
which is based on limiting serial dilution of treated parasites and re-growth monitoring. This methodology allows to
precisely determine the killing rate of antimalarial compounds, which can be quantified by the parasite reduction ratio and
parasite clearance time, which are key mode-of-action parameters. Importantly, we demonstrate that this technique readily
permits to determine compound killing activities that might be otherwise missed by traditional, metabolism-based
techniques. The analysis of a large set of antimalarial drugs reveals that this viability-based assay allows to discriminate
compounds based on their antimalarial mode-of-action. This approach has been adapted to perform medium throughput
screening, facilitating the identification of fast-acting antimalarial compounds, which are crucially needed for the control
and possibly the eradication of malaria.
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Introduction
With more than 220 million cases and 781,000 deaths reported
in 2009, the heavy malaria burden demands urgent solutions [1].
Due to renewed efforts and investments, the number of fatalities
has been, however, constantly decreasing since 2004 and led the
malaria community to re-embark on the long-term goal of
eradicating this parasitic disease [2]. This ambitious endeavor
will require innovative tools to be widely available, including
innovative antimalarial drugs, to ensure the best possible control of
this disease and, hopefully, its eradication [3]. New chemotypes
and new modes-of-action are needed not only to address
eradication-specific objectives but also to replace drugs loosing
efficacy due to the advent of resistant parasites [3]. A critical
example of the latter comes from artemisinin derivatives, which
are used as combination for first-line therapy in the vast majority
of endemic countries. Resistance to artemisinins seems to be
emerging in South-East Asia, as characterized by in vivo delayed
parasite clearance times (PCTs) [4]. Not only genetic markers to
monitor this emerging resistance are missing, but so are potential
replacement drugs [5,6]. This situation underlines our current
need for new antimalarial drugs, which should ideally have the
fastest possible speed-of-action, in order to maximize therapeutic
efficacy and minimize the in-patient opportunity window for
resistant parasite selection and dissemination.
A number of in vitro techniques have been developed to
investigate the effect of drug treatment on asexual parasite survival
and growth, and are used for both drug development and
resistance monitoring studies [7]. Standard techniques use
different approaches, but they all have in common to measure
the growth inhibition of intraerythrocytic parasites after their
exposure to antimalarial compounds for a variable amount of
time, generally between 24 and 96 hours. This measure is
obtained through either counting parasites by microscopy,
measuring the presence of nucleic acids, specific proteins or
metabolites, or the incorporation of precursor thereof, or
measuring the activity of parasite specific enzymes. The most
simple assay is the ‘‘WHO micro-test’’, which was established in
1978 and is based on the measurement of schizont maturation by
microscopic examination of thick blood films after 24 or 48 hours
of drug treatment [8]. This assay requires only simple material but
is very labor intensive and does not permit to investigate large set
of compounds simultaneously. These limitations prompted for the
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assays. These rely on the incorporation of radio-labeled
hypoxanthine or other metabolic precursor as a measure of
parasite growth [9,10]. In contrast to the ‘‘WHO micro-test’’,
drug treatment can be extended for up to 96 hours and the onset
and duration of the labeled precursor incorporation can be
adapted, improving measurement flexibility and reproducibility.
Importantly, these assays can be, at least partially, automated and
are therefore amenable to screening large set of compounds.
Additional assays, which avoid the use of radio-labeled material
and of relatively expensive scintillation counters have been more
recently developed and are based on the measurement of enzyme
presence or activity. The parasite lactate dehydrogenase (pLDH)
enzyme is involved in the glycolysis pathway and can be used as a
marker for the parasite presence. Colorimetric as well as
immunodetection-based assays have been developed to measure
this protein both, in laboratory and field conditions [11,12]. The
histidine-rich protein 2 (HRP2) is another parasite specific
protein which can be measured by immunodetection, providing
a precise estimation of the parasite growth rate [13]. Taking
advantage of the fact that erythrocytes are devoid of DNA
material, alternative methods have been developed to quantify
the parasite nucleic acids, using fluorescent dyes such as SYBR
Green or DAPI [14,15]. Finally, flow cytometry has also been
used to measure light depolarization by heamozoin or DNA
content, providing new methods to evaluate drug potency
[16,17]. These assays differ in sensitivity, application, and cost,
but they all have in common to measure parasite viability in an
indirect manner. Relying on proxies to measure viability can
have a significant impact on the results obtained with these
different assays and might render their interpretation particularly
challenging or erroneous [18]. For instance, viable but metabol-
ically inactive parasites will be measured as dead. This scenario is
naturally occurring during the parasite life cycle, such as in
mature gametocytes or P. vivax hypnozoites, which are arrested in
G0 [19,20]. The converse is also true; parasites committed to
death can still display metabolic activities or steady levels of
marker expression and be classified as viable by the aforemen-
tioned assays. Such a situation can be induced by drug treatment
itself, as exemplified by the choline analog T3/SAR97276 [18].
This compound efficiently kills P. falciparum after 2 hours of
exposure, however pLDH- and HRP2-based assays fail to detect
these effects, suggesting that ongoing marker accumulation is
masking it. Delayed parasite death, as observed with different
antibiotics, including azithromycin and clindamycin, will also
lead to erroneous viability assumptions from assay based on
microscopy observations or metabolic activities [21,22]. It is also
possible that drug treatment might directly affect the metabolic
pathways measured, without altering parasites viability, which
would also lead to erroneous measurements. These different
situations show that metabolic activity and viability are two
parameters which can be uncoupled either naturally or in
response to drug treatment and that relying on the first to
measure the latter can be a possible source of artefacts. Moreover
these assays do not permit to directly measure the speed-of-action
of antimalarial compounds on parasite viability, which is
nevertheless a crucial parameter for anti-infective activities and
clinical efficacy.
The net effect of antimalarial compounds is primarily mediated
by their ability to kill parasites and decrease parasitemia so that
patient cure can be achieved and parasites recrudescence
prevented. Killing rates can be estimated in vivo by the parasite
reduction ratio (PRR), which is the ratio between parasitemia at
the onset of drug treatment and 48 hours later, corresponding to
one asexual parasite life cycle [23]. The reduction of circulating
parasitized erythrocytes generally follows a log-linear curve and
this measure can be used as a predictive therapeutic index. PRR
values vary greatly, with fast-killing drugs, such as artemisinin,
achieving up to 99.99% decrease in parasitemia during one life
cycle, resulting in an in vivo apparent PRR in the order of
magnitude of 10
3–10
4, while slower ones, such as clindamycin,
might exert a PRR of only 10 [24,25]. Beyond the killing rate
itself, the effect of antimalarial drugs also depends on the type of
growth inhibition involved. Cytotoxic drugs, by actively killing
parasites, generally display a high level of efficacy while cytostatic
drugs, such as atovaquone [26], might not completely eliminate
circulating parasites and lead to treatment failure and resistance
selection. As illustrated above, metabolism-based assays are
generally poorly suited tools to discriminate between cytotoxic
and cytostatic activities.
We present here an extensive set of data using an in vitro
methodology developed to circumvent the limitations of classical
metabolism-based assays in measuring anti-malarial activities and
compound killing rates. This approach is based on the direct
measurement of intraerytrocytic P. falciparum viability in response
to drug treatment over time. In vitro PRR as well as PCT values
can be derived from these measures. Moreover, drug lag phases,
that is the time required for a drug to achieve its maximal killing
effect, can be precisely identified and timed. The detailed
characterization of several antimalarial drugs from various
chemical classes is presented, providing both a validation of our
methodology as well as benchmark data for further studies on
compounds in development.
Results
Assessing P. falciparum viability in vitro
A comprehensive methodology has been developed to directly
measure the net effect of chemical compounds on the viability of
intraerythrocytic asexual forms of P. falciparum parasites
(Figure 1A). The principle of the method is the following. An
initial inoculum of 10
6 intraerythrocytic parasites per milliliter, as
determined by microscopy, is established at 0.5% parasitemia and
2% hematocrit. These conditions are exactly identical to the ones
used for standard IC50 determination using a tritiated [
3H]-
hypoxanthine incorporation assay [9]. To avoid multiple infec-
tions, original cultures are incubated under shaking conditions.
Resulting cultures present less than 1% erythrocytes with multiple
infections. Once drug treatment is initiated, the effect of the
inhibitor on parasite viability is monitored by taking out an aliquot
corresponding to 10
5 parasites of the initial population every
24 hours, washing it thoroughly, adding fresh erythrocytes and
performing serial dilutions in a microtiter plate. The number of
parasites in the initial inoculum is calculated by performing the
same actions with an aliquot of the culture before starting
treatment. The limiting serial dilution culture is maintained for up
to 28 days and the presence of growing parasites is terminally
determined in each well by using any standard technique able to
detect parasite growth, such as pLDH detection or [
3H]-
hypoxanthine incorporation. The number of viable parasites
initially present in the aliquot, that is the number of parasites able
to recrudesce upon removal of the drug, can then be back-
calculated based on the most diluted well able to render growth.
By repeating this procedure for multiple time points, here every
24 hours for up to 120 hours, it is possible to obtain a direct
measurement of parasite viability over time in response to drug
treatment. In vitro PRR is calculated as the decrease in viable
parasites over 48 hours, that is one parasite life cycle, and is a
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investigated (Figure 1B). Hence, a compound leaving 10
3 parasites
alive out of 10
5 after 48 hours of treatment has a PRR of 10
2 (10
5/
10
3) or log10(PRR) of 2, hereafter referred to as log(PRR). A ‘‘lag
phase’’ is considered to occur for as long as drug treatment does
not produced the maximal rate of killing, and this period of time is
excluded for PRR calculation. In a practical way, 0–24 or 0–
48 hours stretches are considered part of the lag phase when
estimated reduction of parasite viability over 48 hours, (extrapo-
lated from 0–24 hours in the first case), is more than one order of
magnitude below the calculated PRR using the linear stretch of
the profile. It is important to note that a lag phase is not observed
in all profiles. 99.9% PCT, that is the time needed to clear 99.9%
of the initial parasite population, is determined using a regression
calculated on the log-linear phase of the parasite reduction and
takes the lag phase into account (Figure 1B). In summary,
measuring parasite viability over time in response to drug
treatment allows to determine key in vitro parameters of the
compound killing rate such as lag phase, PRR and 99.9% PCT
values.
Several steps have been undertaken to validate this viability-
based approach. First, aliquots of a known number of parasites, as
determined by microscopy, have been used to evaluate the
precision with which the serial limiting dilution technique allows to
calculate the number of viable parasites. 1/2, 1/3, and 1/10
dilutions of parasite aliquots have been performed (Figure S1).
Every dilution factor tested could accurately be used to back
calculate the initial number of parasite population, with values
ranging from 10
4.7 to 10
5.2 for aliquots of 10
5 parasites. 1/3
dilutions have been further used for the experiments presented in
this study. Because drugs vary in potency and in order to compare
their effects, treatments were performed at concentrations based
on the drug-specific 50% inhibitory concentration (IC50), which is
the concentration required to inhibit the growth of a parasite
population by 50%. IC50 values for the drugs investigated in the
present study have been determined in house using a classical
hypoxanthine incorporation based assay (Table S1) and, if not
otherwise stated, concentrations corresponding to 10 fold IC50
have been used for the experiments reported here. Moreover, to
ascertain a constant level of parasite exposure to drugs, the latter
Figure 1. Schematic representation of the in vitro PRR assay. A. Intraerythrocytic P. falciparum cultured at 0.5% parasitemia and 2%
hematocrit is treated with drugs. The medium is exchanged and the drug replenished every 24 hours. Aliquots corresponding to 10
5 parasites are
taken out at defined time points, washed, and free-drug parasites cultured with fresh erythrocytes under limiting serial dilution conditions (see
Material and Methods). Parasite growth is subsequently monitored after 21 days and confirmed after 28 days, allowing to calculate the initial number
of viable parasite in the aliquot. B. Parasite viability measurement allows in turn to determine the drug lag phase (i.e. time needed to reach the
maximal rate of killing), PRR over one life cycle, and 99.9% PCT (i.e. the time needed to decrease the number of viable parasites by 3 –log units). The
data presented in this panel are for illustration purpose only. Axe Y shows log (viable parasites +1) to allow representation of logarithms when
counting of number of viable parasites is equal to zero.
doi:10.1371/journal.pone.0030949.g001
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media, which is especially important for rapidly degrading
compounds, such as artemisinin [27]. Artemisinin treatment led
to a rapid decrease in viable parasites, from 10
5 to virtually 0 in
48 hours (see below). However if the initial drug level is not kept
relatively constant, by replacing the media every 24 hours, the
number of viable parasite increases at 96 and 120 hours after
drug addition (Figure S2). This suggests that rapid artemisinin
degradation, to a level below the minimum inhibitory concen-
tration, might permit surviving parasites to resume an active
growth. Degradation of artemisinin in culture media has been
confirmed by quality control analysis of the media (data not
shown).
Metabolism is not a good surrogate of parasite viability
To explore the drug antimalarial effects on metabolism and
parasite viability, we have investigated compounds with very
different antimalarial mechanism of action: atovaquone, azithro-
mycin, and artemisinin. Atovaquone is an ubiquinone analog that
disrupts electron transport chain function by targeting the
cytochrome bc1 complex of Plasmodium spp. and is currently used
as a treatment in combination with proguanil [28]. Azithromycin
is a widely used antibiotic with demonstrated antimalarial activity
but showing a delayed death phenotype on malaria parasites
possibly through inhibition of the bacterial-like apicoplast
translation machinery [21]. We compared the effect of these
drugs on parasite hypoxanthine incorporation, as a measure of
metabolic activity, and on the number of parasites alive after
treatment, as described above.
Standard [
3H]-hypoxanthine incorporation assay was used to
construct dose response curves and calculate IC50 of 1 and 32 nM
for atovaquone and artemisinin respectively (Table S1). In these
conditions, azithromycin did not produce any reduction of [
3H]-
hypoxanthine incorporation when compared with the control,
even at the highest concentration tested (10 mM). However, an
IC50 of 0.27 mM, could be determined by extending the treatment
time to 96 hours, confirming the time delayed phenotype
described for this class of compounds. This IC50 value was used
in the parasite viability assay.
The percentages of hypoxanthine incorporation observed after
48 hours at 106IC50, relative to controls without drug treatment
were negligible for artemisinin and atovaquone but 100% in the
case of azithromycin (Figure 2A). Parasite viability was estimated
under exactly the same conditions, that is after 48 hours of
treatment at 106 IC50. Virtually no viable parasites were found
after artemisinin treatment (ca. 5 log reduction in parasite load), in
agreement with the absence of metabolic activity under these
conditions (Figure 2B). However, in the case of atovaquone treated
parasites, less than 1 log reduction in the number of parasites was
observed despite the absence of metabolic activity. This suggests
that these parasites are not committed to death and would be
wrongly classified as such by metabolism-based assays. The
response to azithromycin treatment displays a mirror image:
treatment produces a decrease of more than 1 log in the parasite
load despite fully metabolically active parasites are observed under
these treatment conditions. These results illustrate the fact that
metabolic activity levels do not always correlate with drug-induced
death rate.
Killing rate of classical antimalarial drugs
The killing rate parameters of an extended set of antimalarial
drugs were determined. These include the quinoline-type
chloroquine, mefloquine, and piperaquine, the amino-alcohols
lumefantrine and pyronaridine, the dihydrofolate reductase
(DHFR) inhibitor pyrimethamine, as well as atovaquone and
artemisinin. Parasite viability time course profiles are presented in
Figure 3A, lag phase, PRR and 99.9% PCT values are reported in
Table 1. For all the compounds investigated, the number of viable
parasites fell below 0.0001% of the starting population after
120 hours of treatment at the latest, indicating that the time-frame
considered is appropriate to fully encompass the activity of these
antimalarials. Two compounds displayed a significant lag phase:
atovaquone for 48 hours and pyrimethamine for 24 hours and are
also the slowest acting ones with log(PRR) and 99.9% PCT values
of 2.9 and 90 hours for atovaquone and 3.5 and 52 hours for
pyrimethamine. Artemisinin, on the other hand, is strikingly faster
than any other compound in this set, with a reduction of parasite
viability below 0.1% in less than 24 hours and a log(PRR) value
higher than 8 (as extrapolated from the first 24 hours of
treatment). It is followed, in decreasing speed-of-action order, by
pyronaridine, lumefantrine, piperaquine, chloroquine, and meflo-
quine with PRR values of 4.8, 4.8, 4.6, 4.5 and 3.7, respectively.
We next analyzed the relationship between IC50, log(PRR), and
99.9% PCT (Figure 3B–C). No significant correlation could be
established between PRRs or PCTs and IC50, indicating the
absence of a direct link between antimalarial potency and killing
rate. Consequently, the speed-of-action of a compound cannot
directly be predicted by its efficiency in blocking parasite
hypoxanthine incorporation. These experiments show that
antimalarial drugs display a wide range of killing rates, with
99.9% PCTs, ranging from less than 24 to 90 hours, as dictated by
Figure 2. Comparison of metabolic and viability assays. A.
P. falciparum radio-labeled hypoxanthine incorporations after 48 hours
of drug treatment at concentrations corresponding to 106 IC50 with
artemisinin, atovaquone, and azithromycin, reported as percentages of
untreated controls. Data are averages of 12 repetitions from two
independent experiments B. P. falciparum viability after 48 hours of
drug treatment at concentrations corresponding to 106 IC50 with
artemisinin, atovaquone, and azithromycin, reported as number of
viable parasite, as determined by limiting serial dilutions. Data are
averages of 4 independent experiments. In both panels, error bars
represent the standard error of the mean (SEM).
doi:10.1371/journal.pone.0030949.g002
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potency.
Determination of the optimal dose for maximal rate of
killing
Relatively large killing rate differences occurred with the
different compounds tested. Considering that they all have been
tested at 106 IC50, these results might reflect suboptimal dosing
and, consequently, underestimated killing rate for some of the
inhibitors. In order to test this hypothesis, in vitro PRR
experiments were conducted with a representative subset of
antimalarial drugs using concentrations corresponding to multiples
of their respective IC50:1 6,3 6,1 0 6, and 1006 (Figure 4).
Atovaquone treatment at 16 IC50 displayed a plateau with a
constant, or slightly increasing parasitemia, indicating that the rate
of killing was compensated by the rate of growth in the treated
culture. Increasing atovaquone concentration to 36IC50 decreas-
es the parasitemia level at which the plateau is reached. This
indicates a net killing effect of the drug, as growth of the remaining
parasites can compensate only partially the degree of killing,
inducing an equilibrium at a parasitemia 2 logs below the starting
Figure 3. Parasite viability in response to various classical antimalarial drugs. A. P. falciparum viability time-course profiles for chloroquine
(chq), mefloquine (mef), piperaquine (pip), artemisinin (art), lumefantrine (lum), pyronaridine (pyro), pyrimethamine (pyri), and atovaquone (ato). Error
bars represent the SEM of at least 4 independent experiments. B. and C. Scatter plots of the compounds tested reporting the IC50 versus the log(PRR)
and 99.9% PCT, respectively. The dotted line in panel B is a log linear regression, the slope thereof is not significantly different from zero (p=0.48).
Data of panel C do not converge enough to establish a regression line.
doi:10.1371/journal.pone.0030949.g003
Table 1. In vitro parasite reduction ratio and clearance time in
response to classical antimalarial drugs.
lag phase (h) log(PRR) 99.9% PCT (h)
artemisinin 0 .8.0
a ,24.0
pyronaridine 0 4.8 29
lumefantrine 0 4.8 32
piperaquine 0 4.6 33
chloroquine 0 4.5 32
mefloquine 0 3.7 43
pyrimethamine 24 3.5 55
atovaquone 48 2.9 90
aestimation based on the first 24 hours of treatment.
doi:10.1371/journal.pone.0030949.t001
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virtually complete parasite clearance with a log(PRR) of 2.9 and a
99.9% PCT of 90 hours, while a further 10 fold increase of drug
concentration did not significantly modify the killing rate profile
observed, confirming that the maximal rate of killing was achieved
at the previous concentration (106 IC50) (Figure 4). Pyrimeth-
amine showed a similar pattern and, although at 16IC50, it also
failed to clear all the parasites within 120 hours, killing was higher
than in the case of atovaquone 16IC50 and similar to 36IC50.
This last concentration (36IC50) appears however to be enough to
reach the maximal killing rate of this compound, with log(PRR)
and 99.9% PCT reaching values similar to the ones seen in
response to 106and 1006IC50 concentrations. For artemisinin,
16 IC50 is similarly not sufficient to clear the parasites within
120 hours. However a killing rate similar to that seen with 106
IC50 is achieved with as low as 36 IC50 and is not significantly
different when the parasites are exposed to a dose corresponding
to 1006 IC50. This set of experiments shows that the maximal
killing rate of these compounds is reached with doses correspond-
ing to at most 106IC50. This appears to be true for slow, medium,
as well as fast killing compounds, as illustrated with atovaquone,
pyrimethamine, and artemisinin, respectively. This observation is
also true for additional compounds, including chloroquine and
lumefantrine, which reached maximum killing rate at concentra-
tions below 106IC50 (Figure S3 and Table S2). Interestingly, in
the case of chloroquine maximal rate of killing was observed at
concentrations close to 16 IC50. For both, atovaquone and
pyrimethamine, varying the compound concentration did not alter
the lag phase duration, suggesting that this initial effect does not
depend on the intensity of the parasite exposure to the drugs but
rather on their intrinsic modes-of-action. Altogether, this suggests
106IC50 to be an optimal dose to investigate compound speed-of-
action at the highest rate of killing and to reflect true variations in
compound ability to clear P. falciparum parasites.
Compound rate of killing profile correlates with
antimalarial mode-of-action
It is likely that, all things being equal, compound killing rates are
primarily dictated by the antimalarial mode-of-action and that a
specific profile could be representative for mechanism of killing
(Figure 5). In order to substantiate this possibility, we next
analyzed two sets of compounds sharing either the same
pharmacophore or targeting the same pathway. The first set
includes artemisinin and two derivatives artesunate and arte-
mether, which all contain the endoperoxide bond required for
their antimalarial properties [29]. The second set is composed of
drugs that directly impair the parasite mitochondrial functions and
includes atovaquone, the triazolopyrimidine GW648495 (DSM1
in [30]) and the pyridone GW844520 (Figure S4). GW648495 is
an inhibitor of P. falciparum dihydroorotate dehydrogenase
(DHODH) an essential enzyme of pyrimidine biosynthesis and
GW844520, similarly to atovaquone, has been shown to
specifically inhibit the cytochrome bc1 complex, and to ultimately
impair pyrimidine biosynthesis [30–32]. We determined the P.
falciparum killing rate profiles in response to treatments with these
drugs. Parasites treated with atovaquone, GW648495,
GW844520, and artemisinin were monitored for up to 120 hours.
Considering the rapid action of artemisinin, the response to
artesunate and artemether was measured at 0, and 24 hours only
(Figure 6). The number of viable parasites was decreased by more
Figure 4. Parasite viability time-course in response to various concentrations of drugs. A. P. falciparum viability time-course profiles for
atovaquone, pyrimethamine, and artemisinin at concentrations corresponding to 16,3 6,1 0 6, and 1006their respective IC50. Error bars are SEM of
at least 4 independent experiments. B. Values represented in panel A. No PRR or 99.9% PCT could be calculated for the 16IC50 conditions.
doi:10.1371/journal.pone.0030949.g004
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a slightly delayed parasite reduction profile, as compared to
atovaquone and GW648495. This is mostly due to an extension of
the lag phase of 24 hours, from 48 to 72 hours, as the log(PRR)
values for these three compounds are almost identical, at
approximately 3.0 (Table S3). The 99.9% PCTs for three
compounds are also very similar, with values ranging from 90 to
108 hours (Table S3). Artemether and artesunate displayed a
killing rate apparently similar to artemisinin, with a reduction of 4
log units in parasitemia over 24 hours. (Figure 6). This indicates
that compounds inhibiting identical molecular targets or cellular
functions, display very similar parasite killing rates, substantiating
the idea that drug parasite killing rates are primarily dictated by
their antimalarial mode-of-action.
Single-time point assay allows medium throughput
screening for profiling compounds
The results presented above indicate that measuring the killing
rate profile of candidate antimalarials is a valid approach to
identify fast acting compounds. Since parasite viability measure-
ment in a time-course manner and by serial limiting dilution is a
relatively labor intensive task, which cannot be fully automatized
yet, we explored a single-time point version of the assay, that
would allow to screen a larger number of compounds simulta-
neously. We reasoned that measuring the parasite viability after
72 hours of treatment can be an optimal time point to identify
compounds which have either no lag phase or a limited one, and a
high in vitro PRR value (Figure 5). The effects of 8 compounds,
including some already tested in time course experiments, have
been analyzed using this single time point approach (Figure 7).
Mefloquine, chloroquine, artemisinin, and pyrimethamine in-
duced a reduction in the number of viable parasite higher than
99.9% after 72 hours of treatment, as expected based on the
results of initial time-course experiments. Of note, artemisinin
value is slightly higher as compared to time-course experiments
(0.34 versus 0.13). This is probably due to the fact that drug was
not replenished in this single time-point assay. This approach
successfully identified atovaquone as a slow acting compound, with
a log10 value of 3.4 viable parasites out of 5 from initial inoculum.
Halofantrine and azithromycin were identified as fast-, and slow
acting drugs, with a reduction in viable parasite down to virtually
zero and approximately 3-logs, respectively. Interestingly, myx-
othiazol, which acts as a bc1 inhibitor [28], induced a similar
reduction in the number of viable parasite as atovaquone,
confirming that killing rates correlates with antimalarial mode-
of-action. These data indicate that parasite viability measurement
at a single-time point of 72 hours is a suitable approach to rapidly
identify fast-acting compounds among a large set of candidates.
Discussion
We present here a comprehensive methodology to measure the
net effect of antimalarial compounds on asexual intraerythrocytic
P. falciparum viability. Although other approaches assessing viability
of treated parasites have already been reported [26,33], those have
not studied full time courses for a broad range of compounds,
preventing determination of the killing rate profile for the drug.
Figure 5. Classical antimalarial killing rate profiles. P. falciparum
viability time-course profiles of four classical antimalarial drugs,
illustrating the wide range of speed-of-action measured. Viable parasite
are cleared in response to fast-acting (art and chq), but not slow-acting
(pyri and ato) drugs after 72 hours of treatment.
doi:10.1371/journal.pone.0030949.g005
Figure 6. Parasite viability correlates with the mode-of-action
of antimalarials. P. falciparum viability time-course profiles for
artemisinin, atovaquone, GW648495, and GW844520 measured at 0,
24, 48, 72, 96, and 120 hours. Artemether and artesunate have been
investigated at 24 hours only. Error bars are SEM of at least 4
independent experiments.
doi:10.1371/journal.pone.0030949.g006
Figure 7. Single time-point viability measurement. P. falciparum
viability after 72 hours of treatment with the indicated drugs, reported
as the log of viable parasite+1, as compared to the untreated controls.
The red line represents the threshold of 99.9% parasite reduction. The
data are representative of at least 3 independent experiments.
doi:10.1371/journal.pone.0030949.g007
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inferred from the time needed to observe growth. This can be
influenced by culture conditions or by the time needed to recover
to a steady growth rate following drug exposure, a well
documented phenomenon in the case of antibacterials, known as
the ‘‘postantibiotic effect’’ [34]. We present here the character-
ization of an extended set of drugs using a standardized assay. The
parasite killing rate in response to drug treatment is determined by
directly measuring the number of parasites surviving drug
exposure that is the number of parasites able to resume a
productive growth upon removal of the drug and addition of fresh
erythrocytes. By repeating this measurement over time, it becomes
possible to establish multiple parameters, such as the presence of a
lag phase as well as to calculate in vitro PRR and PCT values.
Importantly, any laboratory strain, including adapted ex vivo
isolates, could potentially be used with the protocol described here.
This could be particularly relevant for tolerance phenotypes,
which do not translate into altered IC50 value, as presently seen in
the case of artesunate [4]. The major advantage of the protocol
presented here is to directly measure parasite viability and to not
rely on parasite metabolic activity or accumulation of specific
molecules. This allows to measure compound killing rates
regardless of their modes-of-action, which is not always the case
with indirect methods [18]. A second advantage is the ability to
directly compare compound killing rates by using treatment
concentrations based on the compound-specific IC50. Direct
measurement of viability is more time- and labor-consuming but
permits to avoid potential bias or artefacts that appear when
viability and parasite metabolic activity become uncoupled. One
recently documented example is the dormancy response induced
by DHA treatment, which might possibly explain the frequent
treatment failures observed with artemisinin treatments [35,36].
More than 1% of P. falciparum treated in vitro with a single-dose of
DHA were found to be able to recover from a dormancy stage
lasting up to 20 days. Parasites becoming dormant in response to
DHA, and possibly other antimalarial drugs, are likely to be
correctly identified as viable if monitored for re-growth for up to
28 days, which might not be the case using metabolism as
surrogate of parasite viability. We also report here a clear case of
disconnection between viability and metabolism in response to
atovaquone and azithromycin treatments. While more than 90%
of parasites are committed to death after 48 hours of treatment
with azithromycin, their metabolism stays unaffected up to that
time and does not allow to detect this fact. Conversely, atovaquone
treated parasites appear to shut down completely their metabolism
while a large fraction of the treated parasites is able to survive
upon removal of the drug. Altogether this shows that metabolism-
based assays do not always fully reflect the killing effects of drugs
on parasites and that direct parasite viability monitoring is better
suited to detect them.
The analysis of an extended set of antimalarial drugs allowed us
to identify different killing rate profiles. The fastest drug tested is
artemisinin with an immediate onset of action, an apparent in vitro
PRR higher than 8.0, and a 99.9% PCT inferior to less than
24 hours. At the other extreme is atovaquone, which displayed a
48 hours lag phase and a low log(PRR) of 2.9, resulting in an
overall 99.9% PCT equal to 90 hours. All the other tested drugs
fell within this relatively large range of values. It is important to
point out that although experiments are performed with
unsynchronized parasites, treated cultures are enriched in ring
forms (ca. 80%) and this would provoke an extended lag phase on
those compounds acting late in the life cycle. The data reported
here are in agreement with the published literature, as artemisinin
is known to be a fast-acting compound and atovaquone a slow one.
For example, clinical PCTs, as determined by microscopy, were
reported to be less than 24 hours and more than 60 hours, for
artemisinin and atovaquone, respectively [25,37]. In vitro and in
vivo PRR, derived from clinical data, are measuring different
phenomena, in vitro PRR measures directly parasite viability while
in vivo PRR is measuring clearance of the parasites by the
organism. In vivo artesunate log(PRR) ranges from 2.9 to 3.8 and is
lower than the value reported here, estimated at 8.0 [38–40].
Similarly, the average PRR for chloroquine observed in clinical
studies is lower than the one reported here at, 2.2 and 4.0,
respectively [41–43]. Available in vivo PRR values are all generally
lower than the ones measured here in vitro, but their ranking is
globally conserved between the in vitro and in vivo situations,
suggesting a reasonable correlation between these measures
(Figure S5) [37–44]. This shift might be due to the fact that in
vivo PRR are established by comparing the parasitemia before
initiating the treatment and 48 hours later without taking lag
phase into account or measuring parasite viability. Other intrinsic
differences between the in vivo physiological situation and the
simpler in vitro settings, such as drug exposure or parasites
sequestration, might also contribute to explain these differences.
Regardless, this suggests that in vitro PRR is, to some extent,
indicative of the therapeutic effect observed in the clinical situation
and should therefore be considered as a valuable assay for drug
development.
Interestingly, treatments with drug concentrations correspond-
ing to 10 times the IC50 appear to be generally sufficient to reach
the maximum in vitro killing rate, regardless of the mode-of-action
of the compounds investigated. This observation might contribute
to define therapeutically optimal dosing regimens for compounds
entering the clinical candidate stage and might facilitate their
characterization at relevant concentrations in efficacy trials. The
investigation of several drugs sharing the same pharmacophore,
such as artemisinin, artesunate, and artemether or targeting the
same parasite organelle, in this case the mitochondrion, such as
atovaquone, GW648495, and GW8445520, indicated that similar
viability profiles were observed among these set of compounds.
This suggests that the protocol presented here is a valuable tool to
investigate compounds with an antimalarial activity of unknown
mode-of-action, as possible mode-of-action could be excluded or
envisaged based on comparison with available data (although
additional information on the compound should be needed to
assign a definitive mode of action) This approach would also allow
to identify potential new mode-of-action, possibly able to
overcome established resistance to current antimalarials.
Speed-of-action is one of the main determinant of antimalarial
compound efficacy and is a crucial clinical parameter, which will
determine not only the in vivo PCT but also the time needed to
clear patient symptoms, which should ideally be as fast as possible.
Another important aspect related to drug speed-of-action is the
resistance opportunity window that is occurring when a drug is
facing parasites in a clinical situation, that is the time window
during which the parasite are exposed to suboptimal drug-level
that might drive selection and transmission of resistant parasites. It
is argued that fast-acting antimalarial will minimize the chance of
resistant mutants to arise within a patient and should be favored.
The in vitro methodology presented here allows to rapidly and
easily identify fast-acting compounds, which present added value
for clinical development. Importantly, speed-of-action and PCT
do not depend on drug potency, prompting the need for a
standardized in vitro method to investigate these factors. The
methodology presented here addresses this issue. We also
identified that 72 hours of treatment is an optimal time-point to
accurately discriminate between fast- and slow-acting compounds,
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with a very slow rate of killing, like GW844520 (Figure 6), would
hardly show an effect at 72 hours and 96 hours treatment should
be more appropriated to detect effects by this kind of compounds.
This streamlined version allows to test more compounds
simultaneously and might be the first step toward establishing a
higher-throughput assay. Such an assay would prove to be very
useful to screen the Tres Cantos Antimalarial Compound set
(TCAMS), as well as other large library of active antimalarial
compounds [45–47]. This would facilitate the identification of
compounds not only potent but also fast acting against P. falciparum
parasites.
Altogether, we present a standardized assay to measure the net
effect of compound on parasite viability, allowing to characterize a
crucial parameter that is the killing rate. We provide data for an
extended set of classical antimalarials which will serve as
benchmark references for future studies and hopefully the
discovery of compounds as rapid as artemisinin derivatives, which
would have the potential to replace them, if needed, and be the
next generation of fast acting antimalarials that we could oppose to
the parasite.
Materials and Methods
Parasite clones and culture conditions
The P. falciparum strain 3D7A used in this study was obtained
from the Malaria Research and Reference Reagent Resource
Center (MR4). Accurate description can be obtained at http://
www.mr4.org. Red blood cells were obtained from the Spanish
Red Cross Blood Bank. P. falciparum were cultured using standard
procedures as described previously [48]. An inoculum of
parasitized red blood cells (PRBC) at 0.5% parasitemia and 2%
hematocrit in RPMI-1640 , 5% AlbuMAX, 2% D-sucrose, 0.3%
L- glutamine and 150 mM hypoxanthine was used for the assays
described below, if not otherwise stated.
Hypoxanthine incorporation assay
Intraerythrocytic P. falciparum growth inhibition by drugs was
determined using a modification of the in vitro [
3H]-hypoxanthine
incorporation method [9]. Briefly, asynchronous cultures (ca. 80%
rings) of PRBC at 2% hematocrit and 0.5% parasitemia with
5 mM hypoxanthine were exposed to 2-fold serial dilutions of the
compounds (Table S4). 96 well plates (Costar #3894) were
incubated 24 h at 37uC, 5% CO2, 5%O2, 95% N2. After 24 h of
incubation, [
3H]-hypoxanthine was added and plates were
incubated for an additional 24 hours. After that period, plates
were harvested on glass fiber filters (Wallac #1450-421) using a
cell harvester 96 (TOMTEC, Perkin Elmer). Filters were dried
and melt-on scintillator sheets (MeltiLex A, PerkinElmer #1450-
441) used to determine the incorporation of [
3H]-hypoxanthine .
Radioactivity was measured using a microbeta counter (Perkin
Elmer). Data are normalized using the incorporation of the
positive control, (PRBC without drug). IC50 values were
determined using Excel and Grafit 5 software. The assays were
performed in at least three independent experiments, and standard
deviations have been calculated.
In vitro parasite viability assay
PRBC, under the conditions mentioned above (asynchronous
cultures with a predominant ring population), are treated with the
selected drugs at concentration corresponding to multiple of their
respective IC50 (Table S1). Drug is renewed daily over the entire
treatment period. Samples of untreated parasite (0 h) and of
treated parasites (24 h, 48 h, 72 h, 96 h and 120 h time-points)
are aliquoted to perform serial dilutions in 96 well plates (Costar
#3894) by adding fresh erythrocytes and new culture media.
Previously to the serial dilutions the drug is washed out using fresh
culture media.
Parasites are cultured for up to 28 days to allow wells with viable
parasites to render detectable parasitemia. Samples are taken to
examine growth using [
3H]-hypoxanthine incorporation (see above,
although any alternative method to detect parasitemia can be used)
at days 21 and 28. The numberof viable parasites is back-calculated
by using the formula X
n21 where n is the number of wells able to
render growth and X the dilution factor (when n=0 number of
viable parasites is estimated as zero). Briefly, 0.1 ml of drug-free
culture (approximately 10
5 parasites) is dispensed in the first well of
a 96 well microtiter plate. For 2-fold serial dilutions 50 ml of culture
containing parasites is transferred to the next well containing 50 ml
of fresh erythrocytes at 2%hematocrit. Foreachtime point 20 serial
dilutions of at least four replicates are performed using two different
96 well plates for parasite culture. This allows to count up to 5610
5
viable parasites per time point. For 3-fold serial dilutions 50 mlo f
culture is transferred to the next well containing 100 ml of fresh
erythrocytes at 2% hematocrit. For each time point 12 serial
dilutions of at least four replicates are performed using two different
96 well plates for parasite culture. This allows to count up to 2610
5
viable parasites per time point. For 10-fold serial dilutions 10 mlo f
culture is transferred to the next well containing 90 ml of fresh
erythrocytesat 2%hematocrit. Foreachtime point 8 serial dilutions
of at least four replicates are performed. This allows to count up to
10
7 viable parasites per time point. Accuracy of the method is
presented in the Results section in the main text and represented in
Figure S1. Lag phase, log(PRR) and PCT values are calculated as
described in the main text.
Supporting Information
Figure S1 Validation of parasite viability determination
by serial dilution. A. A population of 10
6 parasites/ml, as
determined by microscopy, at 0.5% parasitemia and 2%
hematocrit was used to perform 1/2, 1/3, and 1/10 serial limiting
dilutions on aliquots of 10
5 parasites. Parasite growth was
measured after 21 days and the highest dilution displaying growth,
as determined by hypoxanthine incorporation, was considered to
back calculate the initial number of parasite. B. Number of
parasites calculated based on different dilution factors. Error bars
are standard deviations of at least 8 repetitions from one
experiment. The values are representative of three independent
experiments.
(EPS)
Figure S2 Effect of media change for unstable drugs. P.
falciparum viability time-course profiles in response to artemisinin
treatment performed with and without media exchange and drug
replenishment every 24 hours. A few parasites (,3) are still viable
after 48 h treatment without replenishment of the drug.
(EPS)
Figure S3 Parasite viability in response to different
concentrations of drugs. P. falciparum viability time-course
profiles in response to chloroquine and lumefantrine treatments at
concentrations corresponding to 16,3 6,1 0 6, and 1006 their
respective IC50. Error bars are SEM of at least 4 independent
experiments.
(EPS)
Figure S4 Chemical structures of GW648495 and
GW844520.
(EPS)
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data. In vivo PRR data have been estimated from available clinical
trial data and are compared to the in vitro PRR values determined
in this study. Drug ranking is generally conserved between the in
vitro and in vivo situations, with the exception of pyrimethamine. Of
note, pyrimethamine in vivo value is derived from data obtained in
combination with sulfadoxine. Artemether (arte), lumefantrine
(lum), chloroquine (chq), pyrimethamine (pyri), mefloquine (mef),
azithromycin (azi). In vivo PPR value for artemether and
lumefanterine were calculated from clinical trial data available
on the Food and Drug Administration website (http://www.fda.
gov/ohrms/dockets/ac/08/briefing/2008-4388b1-02-Novartis.
pdf).
(EPS)
Table S1 50% inhibitory concentration (IC50) of drugs
used in this study as determined by radio-labeled
hypoxanthine incorporation.
(DOC)
Table S2 In vitro parasite reduction ratio and clearance
time in response to various concentrations of chloro-
quine and lumefantrine.
(DOC)
Table S3 In vitro parasite reduction ratio and clearance
time in response to atovaquone, GW648495X,
GW844520X.
(DOC)
Table S4 Provider and reference number of the com-
pounds used in this study.
(DOC)
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